The cardiovascular risk of schizophrenic patients;Das kardiovaskuläre risiko schizophrener patienten

Neuropsychiatrie

Volumn 21, Issue 4, 2007, Pages 261-266

  Birkhofer, Andreas ^a   Alger, Patricia ^a   Schmid, Georg ^a   Förstl, Hans ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Heart rate variability; Mortality risk; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ACTIMETRY; ARTICLE; CARDIOVASCULAR RISK; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; MORTALITY; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DEATH, SUDDEN, CARDIAC; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART RATE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; MOTOR ACTIVITY; RISK FACTORS; SCHIZOPHRENIA, DISORGANIZED; SCHIZOPHRENIA, PARANOID; SIGNAL PROCESSING, COMPUTER-ASSISTED;

EID: 38949120089     PISSN: 09486259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am.Heart J. 2005;150(6):1115-21.
2. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv.Ment.Dis. 2004;192(1):19-27.
3. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997;8(6):671-7.
4. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am.Heart J. 2005;150(6):1115-21.
5. Silke B, Campbell C, King DJ. The potential cardiotoxicity of antipsychotic drugs as assessed by heart rate variability. J.Psychopharmacol. 2002;16(4):355-60.
6. Curkendall SM, Mo J, Glasser DB, Rose SM, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin.Psychiatry 2004;65(5):715-20.
7. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am.Heart J. 2005;150(6):1115-21.
8. Meincke U, Hoff P, Haverkamp W, Deuschle M. [Cardiac complications in patients with schizophrenic disorders] [Lengthening of QT interval by antipsychotic drugs]. Fortschr.Neurol.Psychiatr. 2007;75(3):133-9.
9. Malaspina D, Bruder G, Dalack GW, Storer S, Van Kammen M, Amador X et al. Diminished cardiac vagal tone in schizophrenia: associations to brain laterality and age of onset. Biol.Psychiatry 1997;41(5):612-7.
10. Agelink MW, Malessa R, Kamcili E, Zeit T, Lemmer W, Bertling R et al. Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: A potential predictor of short-term outcome? Neuropsychobiology 1998;38(1):19-24.
11. Toichi M, Kubota Y, Murai T, Kamio Y, Sakihama M, Toriuchi T et al. The influence of psychotic states on the autonomic nervous system in schizophrenia. Int.J.Psychophysiol. 1999;31(2):147-54.
12. Ikawa M, Tabuse H, Ueno S, Urano T, Sekiya M, Murakami T. Effects of combination psychotropic drug treatment on heart rate variability in psychiatric patients. Psychiatry Clin.Neurosci. 2001;55(4):341-5.
13. Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J.Clin.Psychopharmacol. 2001;21(1):8-13.
14. Silke B, Campbell C, King DJ. The potential cardiotoxicity of antipsychotic drugs as assessed by heart rate variability. J.Psychopharmacol. 2002;16(4):355-60.
15. Kim JH, Yi SH, Yoo CS, Yang SA, Yoon SC, Lee KY et al. Heart rate dynamics and their relationship to psychotic symptom severity in clozapine-treated schizophrenic subjects. Prog.Neuropsychopharmacol.Biol. Psychiatry 2004;28(2):371-8.
16. Muck-Jorgensen P, Mors O, Mortensen PB, Ewald H. The schizophrenic patient in the somatic hospital. Acta Psychiatr.Scand.Suppl 2000;102(407):96-9.
17. Jones LE, Clarke W, Carney CP. Receipt of diabetes services by insured adults with and without claims for mental disorders. Med.Care. 2004;42(12):1167-75.
18. Kosky N. A possible association between high normal and high dose olanzapine and prolongation of the PR interval. J.Psychopharmacol. 2002;16(2):181-2.
19. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am.Heart J. 2005;150(6):1115-21.
20. Appleby L, Thomas S, Ferrier N, Lewis G, Shaw J, Amos T. Sudden unexplained death in psychiatric in-patients. Br.J.Psychiatry 2000;176:405-6.
21. Ruschena D, Mullen PE, Burgess P, Cordner SM, Barry-Walsh J, Drummer OH et al. Sudden death in psychiatric patients. Br.J.Psychiatry 1998;172:331-6.:331-6.
22. Glassman AH, Bigger JT, Jr. Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death. Am J Psychiatry 2001;158(11):1774-82.
23. Haverkamp W, Deuschle M. [Lengthening of QT interval by antipsychotic drugs.]. Nervenarzt 2006;77(3):276-88.
24. Rettenbacher MA, Eder-Ischia U, Bader A, Edlinger M, Hofer A, Hummer M et al. QTc variability in schizophrenia patients treated with antipsychotics and healthy controls. J.Clin.Psychopharmacol. 2005;25(3):206-10.
25. Straus SM, Bleumink GS, Dieleman JP, van der LJ, 't Jong GW, Kingma JH et al. Antipsychotics and the risk of sudden cardiac death. Arch.Intern.Med 2004;164(12):1293-7.
26. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996;93(5):1043-65.
27. Barthel P, Schneider R, Bauer A, Ulm K, Schmitt C, Schomig A et al. Risk stratification after acute myocardial infarction by heart rate turbulence. Circulation 2003;108(10):1221-6.
28. Whitsel EA, Raghunathan TE, Pearce RM, Lin D, Rautaharju PM, Lemaitre R et al. RR interval variation, the QT interval index and risk of primary cardiac arrest among patients without clinically recognized heart disease. Eur.Heart J. 2001;22(2):165-73.
29. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004;109(1):120-4.
30. Ravenswaaij-Arts CM, Kollee LA, Hopman JC, Stoelinga GB, van Geijn HP. Heart rate variability. Ann.Intern.Med. 1993;118(6):436-47.
31. Birkhofer A, Schmidt G, Förstl H. Relationships between mental and cardiac disorders. Fortschr.Neurol.Psychiatr. 2005;72:1-15.
32. Sandercock GR, Bromley PD, Brodie DA. The reliability of short-term measurements of heart rate variability. Int.J.Cardiol. 2005;103(3):238-47.
33. Bauer A, Kantelhardt JW, Barthel P, Schneider R, Makikallio T, Ulm K et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet 2006;367(9523):1674-81.
34. Birkhofer A, Schmidt G, Forstl H. Heart rate variability and depression. Arch.Gen.Psychiatry. 2006;63(9):1052.
35. Gutin B, Howe C, Johnson MH, Humphries MC, Snieder H, Barbeau P. Heart rate variability in adolescents: relations to physical activity, fitness, and adiposity. Med.Sci.Sports Exerc. 2005;37(11):1856-63.
36. Hottenrott K, Hoos O, Esperer HD. [Heart rate variability and physical exercise. Current status]. Herz 2006; 31 (6): 544-52.
37. Beck AT, Ward Ch, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 1961;4:561-71.
38. Spielberger CD. Anxiety and Behaviour. New York: Academic Press; 1966.
39. Mombour W, Kockott G, Fliege K. [The use of the brief psychiatric rating scale (BPRS) by overall and gorham for the diagnosis of acute paranoid psychoses: evaluation of a german translation of the BPRS (author's transl)]. Pharmakopsychiatr.Neuropsychopharmakol. 1975;8(5):279-88.
40. Bauer A, Kantelhardt JW, Bunde A, Barthel P, Schneider R, Malik M et al. Phase-rectified signal averaging detects quasi-periodicities in non-stationary data. Physica 2006;364:423-34.
41. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch.Gen.Psychiatry 2005;62(7):792-8.
42. Ito T, Inoue Y, Sugihara T, Yamada H, Katayama S, Kawahara R. Autonomic function in the early stage of panic disorder: power spectral analysis of heart rate variability. Psychiatry Clin.Neurosci. 1999;53(6):667-72.
43. Scalvini S, Volterrani M, Zanelli E, Pagani M, Mazzuero G, Coats AJ et al. Is heart rate variability a reliable method to assess autonomic modulation in left ventricular dysfunction and heart failure? Assessment of autonomic modulation with heart rate variability Low heart rate variability and sudden cardiac death. Int.J.Cardiol. 1998;67(1):9-17.
44. Bauer A, Kantelhardt JW, Barthel P, Schneider R, Makikallio T, Ulm K et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet 2006;367(9523):1674-81.
45. Toichi M, Kubota Y, Murai T, Kamio Y, Sakihama M, Toriuchi T et al. The influence of psychotic states on the autonomic nervous system in schizophrenia. Int.J.Psychophysiol. 1999;31(2):147-54.
46. Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J.Clin.Psychopharmacol. 2001;21(1):8-13.
47. Malaspina D, Bruder G, Dalack GW, Storer S, Van Kammen M, Amador X et al. Diminished cardiac vagal tone in schizophrenia: associations to brain laterality and age of onset. Biol. Psychiatry 1997;41(5):612-7.
48. Cohen H, Loewenthal U, Matar M, Kotler M. Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br.J.Psychiatry 2001;179:167-71.
49. Ikawa M, Tabuse H, Ueno S, Urano T, Sekiya M, Murakami T. Effects of combination psychotropic drug treatment on heart rate variability in psychiatric patients. Psychiatry Clin.Neurosci. 2001;55(4):341-5.
50. Penttila J, Kuusela T, Scheinin H. Analysis of rapid heart rate variability in the assessment of anticholinergic drug effects in humans. Eur.J.Clin.Pharmacol. 2005;61(8):559-65.
51. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch.Gen.Psychiatry 2005;62(7):792-8.